U.S., Jan. 8 -- ClinicalTrials.gov registry received information related to the study (NCT07322263) titled 'Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC' on Dec. 01, 2025.
Brief Summary: The goal of this clinical trial is to learn whether a combination of two chemotherapy drugs, Gemcitabine and Docetaxel, can treat high-grade non-muscle-invasive bladder cancer (HG-NMIBC) in adults whose cancer failed conventional BCG therapy. The drugs are given directly into the bladder (intravesically), one immediately after the other.
The study will also assess the safety of this treatment.
The main questions it aims to answer are:
Can this drug combination effectively treat HG-NMIBC that did not respond to BCG and help prevent the cancer from...